Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

90715

	registered interest
	date	04/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Animal Experiments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the number of tests on animals conducted in the UK using mitochondrial replacement techniques in each of the last five years; and if he will make a statement.
	tabling member constituency	North Down
	tabling member printed	Lady Hermon
	uin	208267
	answer	answer is ministerial correction date of answer 11/09/2014 answer text <p> </p><p>Experiments on animals have been performed over a number of years with the first successful pronuclear transfer (PNT) technique performed in mice in 1983 by McGrath and Solter. Maternal spindle transfer (MST) is a technique developed in the United States of America in 2009 and has been performed successfully in mice, non-human primates, as well as in sheep and cows. Research on both MST and PNT has been carried out successfully on human embryos. On-going studies of PNT and MST continue to be carried out on mice in the United Kingdom.</p><p> </p><p> </p><p> </p><p>An extensive review of the safety and efficacy of MST and PNT to prevent mitochondrial disease was completed by the Human Fertilisation and Embryology Authority’s Expert Scientific Panel, which includes detailed consideration of animal model studies and can be found on their website:</p><p> </p><p> </p><p> </p><p>www.hfea.gov.uk/docs/Third_Mitochondrial_replacement_scientific_review.pdf</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2014 14:02:52 answering member 4020 label Biography information for George Freeman
	tabling member	1437 label Biography information for Lady Hermon

93283

	registered interest
	date	14/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Anticoagulants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 12 July 2014 to Question 206057, on anticoagulants, what plans the National Institute for Health and Care Excellence has to update that guidance.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	210583
	answer	answer is ministerial correction date of answer 17/10/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) regularly reviews the need to update its published guidance in order to take account of the latest available evidence.</p><p> </p><p> </p><p> </p><p>We understand that NICE considered updating its technology appraisal guidance on bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230) in 2012 and decided, following consultation with stakeholders, to incorporate the recommendations into its clinical guideline on myocardial infarction with ST-segment elevation (CG167). The guideline was published in July 2013 and NICE has advised that it will undergo a surveillance review two years after its publication, expected in July 2015.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/10/2014 12:35:32 answering member 4020 label Biography information for George Freeman
	tabling member	4036 label Biography information for Luciana Berger

91470

	registered interest
	date	10/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Antidepressants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of trends in the prescribing of anti-depressants during the recent recession.
	tabling member constituency	Vale of Clwyd
	tabling member printed	Chris Ruane
	uin	209039
	answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>The particular indication that a medicine is prescribed for is not known. Information on the number of prescription items indicated for anti-depressant dispensed in the community since 1991, as defined in the British National Formulary (BNF) section 4.3 Anti-depressant Drugs. is shown in the following table. The number of prescription items dispensed per 100,000 population is also provided for context.</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="3"><p>Antidepressant prescription items dispensed in the community in England and items per 100,000 population</p></td></tr><tr><td><p>Year</p></td><td><p>Prescription items</p></td><td><p>Items per 100,000 population</p></td></tr><tr><td><p>1991</p></td><td><p>8,953,900</p></td><td><p>18,703</p></td></tr><tr><td><p>1992</p></td><td><p>9,914,330</p></td><td><p>20,656</p></td></tr><tr><td><p>1993</p></td><td><p>10,776,690</p></td><td><p>22,404</p></td></tr><tr><td><p>1994</p></td><td><p>11,816,438</p></td><td><p>24,501</p></td></tr><tr><td><p>1995</p></td><td><p>13,227,137</p></td><td><p>27,338</p></td></tr><tr><td><p>1996</p></td><td><p>14,960,610</p></td><td><p>30,834</p></td></tr><tr><td><p>1997</p></td><td><p>16,822,563</p></td><td><p>34,568</p></td></tr><tr><td><p>1998</p></td><td><p>18,424,473</p></td><td><p>37,739</p></td></tr><tr><td><p>1999</p></td><td><p>20,108,130</p></td><td><p>41,009</p></td></tr><tr><td><p>2000</p></td><td><p>22,021,840</p></td><td><p>44,730</p></td></tr><tr><td><p>2001</p></td><td><p>24,342,713</p></td><td><p>49,227</p></td></tr><tr><td><p>2002</p></td><td><p>26,329,382</p></td><td><p>52,999</p></td></tr><tr><td><p>2003</p></td><td><p>27,657,990</p></td><td><p>55,399</p></td></tr><tr><td><p>2004</p></td><td><p>28,995,511</p></td><td><p>57,766</p></td></tr><tr><td><p>2005</p></td><td><p>29,389,874</p></td><td><p>58,076</p></td></tr><tr><td><p>2006</p></td><td><p>31,037,983</p></td><td><p>60,900</p></td></tr><tr><td><p>2007</p></td><td><p>33,839,594</p></td><td><p>65,860</p></td></tr><tr><td><p>2008</p></td><td><p>35,960,539</p></td><td><p>69,401</p></td></tr><tr><td><p>2009</p></td><td><p>39,140,459</p></td><td><p>74,987</p></td></tr><tr><td><p>2010</p></td><td><p>42,787,966</p></td><td><p>81,280</p></td></tr><tr><td><p>2011</p></td><td><p>46,677,813</p></td><td><p>87,894</p></td></tr><tr><td><p>2012</p></td><td><p>50,167,201</p></td><td><p>93,781</p></td></tr><tr><td><p>2013</p></td><td><p>53,326,550</p></td><td><p>98,999</p></td></tr><tr><td colspan="3"><p>Sources: Office of National Statistics and Prescription Cost Analysis provided by the Health and Social Care Information Centre</p></td></tr></tbody></table><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:52:51 answering member 4020 label Biography information for George Freeman
	tabling member	534 label Biography information for Chris Ruane

92008

	registered interest
	date	26/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Antidepressants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many incidents have been recorded by the NHS of Citalopram leading to the deterioration of a patient's health in the last five years.
	tabling member constituency	Richmond Park
	tabling member printed	Zac Goldsmith
	uin	209345
	answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines (CHM) through the spontaneous reporting scheme, the Yellow Card Scheme.</p><p> </p><p><strong> </strong></p><p> </p><p>The Yellow Card Scheme collects information relating to suspected adverse drug reactions, which include both serious and non-serious effects which a doctor or patient suspects may have been due to a medicine. The MHRA has received a total of 1207 suspected ADR reports in association with citalopram between 1 January 2009 and 31 August 2014. This number includes reports received directly from healthcare professionals, patients and indirectly through pharmaceutical companies which have a legal obligation to report suspected ADRs. The number of reports received directly from the NHS cannot be determined.</p><p> </p><p> </p><p> </p><p>The inclusion of a particular ADR in a report does not necessarily mean it has been caused by the drug, only that the reporter had a suspicion it may have, or it had a close temporal relationship to the administration of the suspect drug. The fact that symptoms occur after a treatment does not necessarily mean that they have been caused by the drug itself, as underlying illnesses and other conditions may be responsible.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/10/2014 16:18:40 answering member 4020 label Biography information for George Freeman
	tabling member	4062 label Biography information for Lord Goldsmith of Richmond Park

91990

	registered interest
	date	26/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Antidepressants: Harlow
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many prescriptions were issued for antidepressant medication in Harlow constituency in each of the last 10 years.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	209512
	answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>Information is not available in the format requested. The following table shows numbers of prescriptions issued for antidepressant medication for West Essex Primary Care Trust (PCT) from 2010-11 to 2012-13 and for West Essex Clinical Commissioning Group (CCG) for 2013-14. Data is not available at constituency level or prior to 2010-11.</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="5"><p>Numbers of antidepressant prescription items written in the specified organisations and dispensed in the community by the specified financial years</p></td></tr><tr><td><p>Year</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012/13</p></td><td><p>2013-14</p></td></tr><tr><td><p>West Essex PCT</p></td><td><p>233,181</p></td><td><p>252,536</p></td><td><p>258,873</p></td><td><p>-</p></td></tr><tr><td><p>West Essex CCG</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>274,969</p></td></tr></tbody></table><p> </p><p><em>Source: </em>Health and Social Care Information Centre Prescribing Analysis and CosT tool (PACT) system</p><p> </p><p> </p><p> </p><p><em>Notes:</em></p><p> </p><p>1. The data in the table relate to prescriptions of items from the British National Formulary (BNF) section 4.3.</p><p> </p><p>2. The data available in PACT is a rolling 60-month dataset, so only the number of prescriptions in the last four full financial years is available.</p><p> </p><p>3. PACT covers prescriptions prescribed by GPs, nurses, pharmacists and others in England and dispensed in the community in the UK. For data at PCT level, prescriptions written by a prescriber located in a particular PCT but dispensed outside that PCT will be included in the PCT in which the prescriber is based. Prescriptions written in England but dispensed outside England are included.</p><p> </p><p>4. Prescriptions written in hospitals/clinics that are dispensed in the community, prescriptions dispensed in hospitals, dental prescribing and private prescriptions are not included in PACT data. It is important to note this as some BNF sections have a high proportion of prescriptions written in hospitals that are dispensed in the community including, for example, BNF chapter 4, <em>Central Nervous System</em>. These prescriptions are not included in PACT data.</p><p> </p><p>5. Prescriptions are written on a prescription form known as a FP10. Each single item written on the form is counted as a prescription item.</p><p> </p><p>6. The PACT system uses the therapeutic classifications defined in the BNF. Information on why a drug is prescribed is not available in this dataset. Since drugs can be prescribed to treat more than one condition, it may not be possible to separate the different conditions for which a drug may have been prescribed.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:38:10 answering member 4020 label Biography information for George Freeman
	tabling member	3985 label Biography information for Robert Halfon

100887

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211918
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100876

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211846
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:</p><p> </p><p>3.1.1 Adrenoceptor agonists</p><p> </p><p>3.1.2 Antimuscarinic bronchodilators</p><p> </p><p>3.1.3 Theophylline</p><p> </p><p>3.2 Corticosteroids</p><p> </p><p>3.3.1 Cromoglicate and related therapy</p><p> </p><p>3.3.2 Leukotriene receptor antagonists</p><p> </p><p>3.4.2 Allergen immunotherapy (omalizumab only)</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="11"><p>Cost of drugs for the treatment of asthma, England<sup>1</sup></p></td></tr><tr><td rowspan="2"><p>Drug name</p></td><td colspan="5"><p>Primary Care (£ millions)</p></td><td colspan="5"><p>Secondary Care (£ millions)</p></td></tr><tr><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Aclidinium Bromide</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.02</p></td><td><p>1.62</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.00</p></td><td><p>0.03</p></td></tr><tr><td><p>Aminophylline</p></td><td><p>1.25</p></td><td><p>1.18</p></td><td><p>1.12</p></td><td><p>1.08</p></td><td><p>1.05</p></td><td><p>0.30</p></td><td><p>0.29</p></td><td><p>0.21</p></td><td><p>0.23</p></td><td><p>0.22</p></td></tr><tr><td><p>Beclometasone Dipropionate</p></td><td><p>84.26</p></td><td><p>87.72</p></td><td><p>90.30</p></td><td><p>97.56</p></td><td><p>102.39</p></td><td><p>1.62</p></td><td><p>1.53</p></td><td><p>1.41</p></td><td><p>1.49</p></td><td><p>1.42</p></td></tr><tr><td><p>Budesonide</p></td><td><p>140.35</p></td><td><p>149.03</p></td><td><p>158.82</p></td><td><p>169.14</p></td><td><p>177.00</p></td><td><p>1.29</p></td><td><p>1.14</p></td><td><p>1.14</p></td><td><p>1.27</p></td><td><p>1.41</p></td></tr><tr><td><p>Budesonide/ Formoterol</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>2.75</p></td><td><p>2.94</p></td><td><p>2.89</p></td><td><p>3.10</p></td><td><p>3.29</p></td></tr><tr><td><p>Ciclesonide</p></td><td><p>0.84</p></td><td><p>0.95</p></td><td><p>1.03</p></td><td><p>1.12</p></td><td><p>1.25</p></td><td><p>0.01</p></td><td><p>0.02</p></td><td><p>0.02</p></td><td><p>0.02</p></td><td><p>0.03</p></td></tr><tr><td><p>Fluticasone</p></td><td><p>366.24</p></td><td><p>380.56</p></td><td><p>387.89</p></td><td><p>392.95</p></td><td><p>396.10</p></td><td><p>1.00</p></td><td><p>0.93</p></td><td><p>0.91</p></td><td><p>1.00</p></td><td><p>0.99</p></td></tr><tr><td><p>Fluticasone/ Salmeterol</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>11.46</p></td><td><p>11.56</p></td><td><p>10.69</p></td><td><p>10.82</p></td><td><p>10.48</p></td></tr><tr><td><p>Formoterol Fumarate</p></td><td><p>5.18</p></td><td><p>4.87</p></td><td><p>4.68</p></td><td><p>4.85</p></td><td><p>4.93</p></td><td><p>0.10</p></td><td><p>0.08</p></td><td><p>0.07</p></td><td><p>0.06</p></td><td><p>0.06</p></td></tr><tr><td><p>Glycopyrronium Bromide</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.01</p></td><td><p>2.30</p></td><td><p>0.58</p></td><td><p>0.62</p></td><td><p>0.70</p></td><td><p>0.79</p></td><td><p>1.00</p></td></tr><tr><td><p>Indacaterol Maleate</p></td><td><p>-</p></td><td><p>0.04</p></td><td><p>0.30</p></td><td><p>0.92</p></td><td><p>1.47</p></td><td><p>-</p></td><td><p>0.00</p></td><td><p>0.00</p></td><td><p>0.02</p></td><td><p>0.04</p></td></tr><tr><td><p>Ipratropium Bromide</p></td><td><p>16.15</p></td><td><p>15.02</p></td><td><p>13.74</p></td><td><p>10.32</p></td><td><p>8.61</p></td><td><p>2.74</p></td><td><p>2.84</p></td><td><p>2.59</p></td><td><p>2.65</p></td><td><p>2.70</p></td></tr><tr><td><p>Mometasone Furoate</p></td><td><p>0.36</p></td><td><p>0.31</p></td><td><p>0.26</p></td><td><p>0.23</p></td><td><p>0.21</p></td><td><p>0.76</p></td><td><p>0.71</p></td><td><p>0.61</p></td><td><p>0.63</p></td><td><p>0.67</p></td></tr><tr><td><p>Montelukast</p></td><td><p>38.91</p></td><td><p>43.01</p></td><td><p>46.96</p></td><td><p>51.71</p></td><td><p>31.31</p></td><td><p>0.98</p></td><td><p>1.02</p></td><td><p>1.03</p></td><td><p>1.16</p></td><td><p>0.81</p></td></tr><tr><td><p>Omalizumab</p></td><td><p>0.00</p></td><td><p>0.01</p></td><td><p>0.03</p></td><td><p>0.15</p></td><td><p>0.12</p></td><td><p>5.97</p></td><td><p>9.22</p></td><td><p>12.16</p></td><td><p>14.65</p></td><td><p>17.86</p></td></tr><tr><td><p>Salbutamol</p></td><td><p>83.15</p></td><td><p>82.64</p></td><td><p>60.58</p></td><td><p>60.37</p></td><td><p>59.95</p></td><td><p>3.78</p></td><td><p>3.77</p></td><td><p>3.36</p></td><td><p>3.38</p></td><td><p>3.29</p></td></tr><tr><td><p>Salmeterol</p></td><td><p>48.80</p></td><td><p>45.16</p></td><td><p>41.87</p></td><td><p>36.72</p></td><td><p>34.04</p></td><td><p>0.87</p></td><td><p>0.74</p></td><td><p>0.59</p></td><td><p>0.53</p></td><td><p>0.47</p></td></tr><tr><td><p>Terbutaline Sulphate</p></td><td><p>8.61</p></td><td><p>8.20</p></td><td><p>7.61</p></td><td><p>7.43</p></td><td><p>7.18</p></td><td><p>0.18</p></td><td><p>0.16</p></td><td><p>0.14</p></td><td><p>0.14</p></td><td><p>0.15</p></td></tr><tr><td><p>Theophylline</p></td><td><p>2.18</p></td><td><p>2.17</p></td><td><p>2.15</p></td><td><p>2.22</p></td><td><p>2.26</p></td><td><p>0.12</p></td><td><p>0.11</p></td><td><p>0.11</p></td><td><p>0.11</p></td><td><p>0.11</p></td></tr><tr><td><p>Tiotropium</p></td><td><p>113.61</p></td><td><p>129.98</p></td><td><p>149.81</p></td><td><p>169.35</p></td><td><p>185.24</p></td><td><p>5.69</p></td><td><p>6.03</p></td><td><p>6.22</p></td><td><p>6.64</p></td><td><p>6.87</p></td></tr><tr><td><p>Zafirlukast</p></td><td><p>0.79</p></td><td><p>0.71</p></td><td><p>0.71</p></td><td><p>0.70</p></td><td><p>0.69</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td></tr><tr><td><p>Other drugs<sup>2</sup></p></td><td><p>0.90</p></td><td><p>0.79</p></td><td><p>0.66</p></td><td><p>0.62</p></td><td><p>0.60</p></td><td><p>0.04</p></td><td><p>0.07</p></td><td><p>0.15</p></td><td><p>0.26</p></td><td><p>0.46</p></td></tr><tr><td><p>Total</p></td><td><p>911.6</p></td><td><p>952.3</p></td><td><p>968.5</p></td><td><p>1,007.5</p></td><td><p>1,018.3</p></td><td><p>40.3</p></td><td><p>43.8</p></td><td><p>45.0</p></td><td><p>49.0</p></td><td><p>52.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p> </p><p><sup>2</sup> Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate.</p><p> </p><p>Source:</p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:13:01 answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100885

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211885
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:29 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

93568

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what funding his Department provides for businesses and organisations conducting research into the benefits of natural products in cancer therapy and treatment.
	tabling member constituency	Belfast North
	tabling member printed	Mr Nigel Dodds
	uin	210719
	answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>The Government has funding mechanisms in place for research and development relating to cancer treatments.</p><p> </p><p> </p><p> </p><p>The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the use of natural products in cancer treatment. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £16 million over five years (to 2017) in 14 Experimental Cancer Medicine Centres (ECMCs) across England with joint funding from Cancer Research UK. These centres bring together laboratory and clinical patient-based research to speed up the development of innovative cancer therapies and individualise patient treatment. Researchers at the Leicester ECMC are currently looking at whether curcumin – found in turmeric – can improve drug response in patients with advanced bowel cancer.</p><p> </p><p> </p><p> </p><p>The NIHR manages the Efficacy and Mechanism Evaluation programme, which bridges the gap between preclinical studies and evidence of clinical efficacy. The aim is to secure the progress of new technologies and interventions through their early clinical trials and onto larger, later clinical trials. The programme is funded by the Medical Research Council (MRC) and the NIHR and is not currently funding any studies of the use of natural products in cancer treatment.</p><p> </p><p> </p><p> </p><p>Other sources of funding include the Biomedical Catalyst, which is a funding programme jointly operated by the MRC and Innovate UK. The programme provides responsive and effective support for the best translational life science opportunities arising. Grants are available to UK academics and small and medium enterprises seeking to move their research more quickly from discovery to commercialisation.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/10/2014 15:10:04 answering member 4020 label Biography information for George Freeman
	tabling member	1388 label Biography information for Lord Dodds of Duncairn

90117

	registered interest
	date	01/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the forecast level of expenditure on the Cancer Drugs Fund will be in the 2014-15 financial year.
	tabling member constituency	Bromley and Chislehurst
	tabling member printed	Robert Neill
	uin	207589
	answer	answer is ministerial correction date of answer 08/09/2014 answer text <p>NHS England has oversight of the Cancer Drugs Fund.</p><p>We are advised that NHS England has not published a forecast for expenditure through the Cancer Drugs Fund in 2014-15.</p><p>On 28 August, we announced that the size of the Fund would be increased to £280 million in both 2014-15 and 2015-16.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/09/2014 16:15:08 answering member 4020 label Biography information for George Freeman
	tabling member	1601 label Biography information for Sir Robert Neill